Cargando…
Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies
AIMS: This post hoc analysis assessed the efficacy and safety/tolerability of adjunctive perampanel in patients from China (aged ≥12 years) with focal seizures (FS), with/without focal to bilateral tonic‐clonic seizures (FBTCS), or generalized tonic‐clonic seizures (GTCS). METHODS: Study centers in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871786/ https://www.ncbi.nlm.nih.gov/pubmed/33340263 http://dx.doi.org/10.1111/cns.13458 |
_version_ | 1783649077846605824 |
---|---|
author | Weiping, Liao Dong, Zhou Zhen, Hong Patten, Anna Dash, Amitabh Malhotra, Manoj |
author_facet | Weiping, Liao Dong, Zhou Zhen, Hong Patten, Anna Dash, Amitabh Malhotra, Manoj |
author_sort | Weiping, Liao |
collection | PubMed |
description | AIMS: This post hoc analysis assessed the efficacy and safety/tolerability of adjunctive perampanel in patients from China (aged ≥12 years) with focal seizures (FS), with/without focal to bilateral tonic‐clonic seizures (FBTCS), or generalized tonic‐clonic seizures (GTCS). METHODS: Study centers in China were identified using data from five double‐blind, randomized, phase III studies of adjunctive perampanel (2‐12 mg/day) and their open‐label extensions (OLEx). Efficacy assessments included median percent reduction in seizure frequency per 28 days, and 50% and 75% responder and seizure‐freedom rates. Safety/tolerability assessments included monitoring of treatment‐emergent adverse events (TEAEs). RESULTS: Overall, 277 patients (placebo, n = 79; perampanel, n = 198) were included in the double‐blind safety analysis set. The full analysis set comprised 274 patients (FS, n = 238 [placebo, n = 60; perampanel, n = 178]; FBTCS, n = 120 [placebo, n = 31; perampanel, n = 89]; GTCS, n = 36 [placebo, n = 18; perampanel, n = 18]). Median percent reductions in seizure frequency for placebo vs perampanel were as follows: 16.6% vs 32.4% (FS; P < 0.05) and 39.1% vs 48.2% (FBTCS; not significant [NS]) at 4‐12 mg/day, and 37.9% vs 82.6% (GTCS; NS) at 8 mg/day; 50% responder rates were 31.7% vs 37.4% (FS; NS), 48.4% vs 51.9% (FBTCS; NS), and 33.3% vs 61.1% (GTCS; NS), respectively. Seizure‐freedom rates were 1.7% vs 9.2%, 16.1% vs 25.3%, and 16.7% vs 44.4%, respectively (all NS). Overall, 262 patients entered the OLEx (FS, n = 228; GTCS, n = 34). Perampanel was efficacious for up to four years for FS and FBTCS and up to two years for GTCS. Across the double‐blind and OLEx studies, TEAEs were reported in 65.7% and 81.3% of perampanel‐treated patients, respectively; the most common was dizziness. Efficacy and safety/tolerability outcomes were generally similar between Chinese and non‐Chinese patients. CONCLUSION: Adjunctive perampanel (up to 12 mg/day) may be a suitable treatment for Chinese patients with FS, with/without FBTCS, or GTCS, with similar efficacy and safety/tolerability compared to non‐Chinese patients. |
format | Online Article Text |
id | pubmed-7871786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78717862021-02-17 Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies Weiping, Liao Dong, Zhou Zhen, Hong Patten, Anna Dash, Amitabh Malhotra, Manoj CNS Neurosci Ther Original Articles AIMS: This post hoc analysis assessed the efficacy and safety/tolerability of adjunctive perampanel in patients from China (aged ≥12 years) with focal seizures (FS), with/without focal to bilateral tonic‐clonic seizures (FBTCS), or generalized tonic‐clonic seizures (GTCS). METHODS: Study centers in China were identified using data from five double‐blind, randomized, phase III studies of adjunctive perampanel (2‐12 mg/day) and their open‐label extensions (OLEx). Efficacy assessments included median percent reduction in seizure frequency per 28 days, and 50% and 75% responder and seizure‐freedom rates. Safety/tolerability assessments included monitoring of treatment‐emergent adverse events (TEAEs). RESULTS: Overall, 277 patients (placebo, n = 79; perampanel, n = 198) were included in the double‐blind safety analysis set. The full analysis set comprised 274 patients (FS, n = 238 [placebo, n = 60; perampanel, n = 178]; FBTCS, n = 120 [placebo, n = 31; perampanel, n = 89]; GTCS, n = 36 [placebo, n = 18; perampanel, n = 18]). Median percent reductions in seizure frequency for placebo vs perampanel were as follows: 16.6% vs 32.4% (FS; P < 0.05) and 39.1% vs 48.2% (FBTCS; not significant [NS]) at 4‐12 mg/day, and 37.9% vs 82.6% (GTCS; NS) at 8 mg/day; 50% responder rates were 31.7% vs 37.4% (FS; NS), 48.4% vs 51.9% (FBTCS; NS), and 33.3% vs 61.1% (GTCS; NS), respectively. Seizure‐freedom rates were 1.7% vs 9.2%, 16.1% vs 25.3%, and 16.7% vs 44.4%, respectively (all NS). Overall, 262 patients entered the OLEx (FS, n = 228; GTCS, n = 34). Perampanel was efficacious for up to four years for FS and FBTCS and up to two years for GTCS. Across the double‐blind and OLEx studies, TEAEs were reported in 65.7% and 81.3% of perampanel‐treated patients, respectively; the most common was dizziness. Efficacy and safety/tolerability outcomes were generally similar between Chinese and non‐Chinese patients. CONCLUSION: Adjunctive perampanel (up to 12 mg/day) may be a suitable treatment for Chinese patients with FS, with/without FBTCS, or GTCS, with similar efficacy and safety/tolerability compared to non‐Chinese patients. John Wiley and Sons Inc. 2020-09-08 /pmc/articles/PMC7871786/ /pubmed/33340263 http://dx.doi.org/10.1111/cns.13458 Text en © 2020 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Weiping, Liao Dong, Zhou Zhen, Hong Patten, Anna Dash, Amitabh Malhotra, Manoj Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title | Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title_full | Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title_fullStr | Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title_full_unstemmed | Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title_short | Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies |
title_sort | efficacy, safety, and tolerability of adjunctive perampanel in patients from china with focal seizures or generalized tonic‐clonic seizures: post hoc analysis of phase iii double‐blind and open‐label extension studies |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871786/ https://www.ncbi.nlm.nih.gov/pubmed/33340263 http://dx.doi.org/10.1111/cns.13458 |
work_keys_str_mv | AT weipingliao efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies AT dongzhou efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies AT zhenhong efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies AT pattenanna efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies AT dashamitabh efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies AT malhotramanoj efficacysafetyandtolerabilityofadjunctiveperampanelinpatientsfromchinawithfocalseizuresorgeneralizedtonicclonicseizuresposthocanalysisofphaseiiidoubleblindandopenlabelextensionstudies |